Atkinson Sara E, Khanolkar-Young Saroj, Marlowe Sharon, Jain Suman, Reddy Raj Gopal, Suneetha Sujai, Lockwood Diana N J
Department of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Int J Lepr Other Mycobact Dis. 2004 Mar;72(1):27-34. doi: 10.1489/1544-581X(2004)072<0027:DOIIAI>2.0.CO;2.
This study demonstrates the presence of IL-10 and IL-6, by immunohistochemistry, in the skin lesions of patients with Type 1 reactions. Fifteen patients with Type 1 reaction from Hyderabad, India were included in this study. They were all receiving standardized treatment for Type 1 reactions: a reducing course of daily oral prednisolone for 6 months. Biopsies were taken before treatment and during treatment at weeks 1, 4, and 6 months. IL-13 was observed in the lesions of most patients. By week 4 of treatment, the presence of IL-13, IL-10, and IL-6 in the lesions had decreased significantly. Although some patients showed significant clinical skin sign improvement within one week of therapy, no concomitant decrease or increase in any of the cytokines was observed at this time point. Interestingly, some cytokine activity within the lesions was observed after 6 months of treatment.
本研究通过免疫组织化学方法,证实在Ⅰ型反应患者的皮肤病变中存在白细胞介素-10(IL-10)和白细胞介素-6(IL-6)。本研究纳入了15名来自印度海得拉巴的Ⅰ型反应患者。他们均接受针对Ⅰ型反应的标准化治疗:每日口服泼尼松龙递减疗程,持续6个月。在治疗前以及治疗第1、4和6个月时进行活检。在大多数患者的病变中观察到白细胞介素-13(IL-13)。到治疗第4周时,病变中IL-13、IL-10和IL-6的含量显著下降。尽管一些患者在治疗1周内临床皮肤症状有显著改善,但在这个时间点未观察到任何细胞因子有相应的减少或增加。有趣的是,治疗6个月后在病变中观察到了一些细胞因子活性。